Skip to main content

Table 1 Baseline characteristics of the patients and laboratory data at initiation of tolvaptan

From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites

  Total (n = 170) Discontinued* (n = 90) Continued** (n = 37) p-value * vs. **
Age (years) 63 (21–90) 60 (21–85) 63 (22–90) 0.28
Sex (% of males) 95/170 (56%) 47/90 (52%) 23/37 (62%) 0.31
BW (kg) 61.9 (34.4–143.6) 61.6 (37.4–98.9) 62.9 (34.4–143.6) 0.48
BW after 1 week (kg) 60.9 (32.7–136.2) 61.5 (36.3–103.8) 61.0 (32.7–136.2) 0.75
BW reduction after 1 week (kg) 1.5 (−6.2–17.2) 1.1 (−6.2–7.5) 2.0 (−3.4–17.2) 0.03
Urine volume (mL) 1595 (120–6630) 1450 (120–6630) 1690 (195–4460) 0.77
Etiology of liver disease (%)     0.07
 HCV 48 (28%) 28 (31%) 6 (16%)  
 HBV 12 (7%) 4 (4%) 4 (11%)  
 ALD 48 (28%) 22 (24%) 15 (41%)  
 NAFLD 19 (11%) 7 (8%) 5 (14%)  
 PBC 17 (10%) 7 (8%) 4 (11%)  
 Others 31 (18%) 24 (27%) 4 (11%)  
Complication (%)
 Gastroesophageal varices 109/160 (68%) 62/82 (76%) 21/37 (57%) 0.04
 Hepatocellular carcinoma 54/170 (32%) 26/90 (29%) 13/37 (35%) 0.51
 Hepatic encephalopathy 46/170 (27%) 33/90 (37%) 8/37 (22%) 0.10
Diuretics
 Furosemide dose (mg/day) 20 (0–160) 20 (0–120) 20 (0–80) 0.48
 Spironolactone dose (mg/day) 50 (0–400) 50 (0–400) 50 (0–150) 0.24
 Branched-chain amino acid (%) 150/170 (88%) 76/90 (84%) 35/37 (95%) 0.12
 CART or drainage (%) 84/170 (49%) 47/90 (52%) 15/37 (41%) 0.37
 Denver shunt 6 (4%) 1 (1%) 3 (8%) 0.04
Laboratory data
 Albumin (g/dL) 2.4 (1.5–4.2) 2.4 (1.6–3.6) 2.6 (1.7–4.2) 0.03
 Total bilirubin (mg/dL) 1.9 (0.3–52.4) 2.2 (0.3–52.4) 2.0 (0.4–21.7) < 0.01
 Aspartate aminotransferase (U/L) 48 (10–551) 52 (12–551) 42 (13–171) 0.06
 Alanine aminotransferase (U/L) 28 (3–381) 29 (3–381) 29 (7–144) 0.53
 γ-Glutamyl transpeptidase (U/L) 49 (9–269) 52 (9–269) 48 (9–229) 0.28
 Platelet count (×104/μL) 8.8 (1.5–62.7) 8.8 (2.1–62.7) 7.6 (1.5–23.9) 0.10
 Prothrombin time (PT%) 55.6 (16.3–90.3) 52.5 (16.3–89.0) 54.5 (19.5–90.3) 0.22
 PT/INR 1.31 (0.98–3.17) 1.33 (1.04–3.17) 1.32 (0.98–2.84) 0.36
 Ammonia (μg/dL) 66 (16–269) 60 (24–212) 85 (25–269) 0.11
 α-fetoprotein (ng/mL) 4 (1–142,010) 4 (1–142,010) 4 (1–210) 0.13
 Des-gamma-carboxy (mAU/mL) 68 (3–357,790) 73 (5–357,790) 27 (3–4994) 0.26
 Blood urea nitrogen (mg/dL) 20.9 (5.5–125.3) 22.5 (5.8–64.3) 23.2 (6.0–63.3) 0.86
 Creatinine (mg/dL) 0.99 (0.20–3.30) 1.00 (0.20–2.87) 1.04 (0.44–3.30) 0.28
 eGFR (mL/min/1.73 m2) 53.9 (14.9–250.6) 53.1 (14.9–250.6) 49.5 (16.8–107.2) 0.06
 Serum sodium (mEq/L) 136 (118–145) 135 (118–143) 137 (122–145) 0.01
 Modified Child-Pugh (CP) score 11 (6–14) 11 (8–14) 11 (8–13) 0.05
 MELD score 12 (1–37) 14 (1–37) 12 (2–29) 0.53
  1. n number of patients, BW body weight, HCV hepatitis C virus, HBV hepatitis B virus, ALD alcoholic liver disease, NAFLD non-alcoholic fatty liver disease, PBC primary biliary cholangitis, CART cell-free and concentrated ascites reinfusion therapy, eGFR estimated glomerular filtration rate, INR international normalized ratio, MELD model for end-stage liver disease. Data are represented as the median (range)